Vanguard Group Inc Cti Biopharma Corp Transaction History

Vanguard Group Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$4.2 - $6.01 $1.62 Million - $2.32 Million	386,319 Added 6.93%	5,957,730 $25 Million
Q4 2022 Feb 10, 2023	BUY	$4.45 - $6.17 $3.49 Million - $4.85 Million	785,388 Added 16.41%	5,571,411 $33.5 Million
Q3 2022 Nov 14, 2022	BUY	$5.36 - $7.43 $2.2 Million - $3.04 Million	409,584 Added 9.36%	4,786,023 $27.9 Million
Q2 2022 Aug 12, 2022	BUY	$3.55 - $6.27 $2.76 Million - $4.87 Million	777,024 Added 21.59%	4,376,439 $26.1 Million
Q1 2022 May 13, 2022	BUY	$1.9 - $5.23 $434,340 - $1.2 Million	228,600 Added 6.78%	3,599,415 $16.8 Million

Q4 2021 Feb 14, 2022	SELL	$1.44 - $2.86 $439,472 - $872,840	-305,189 Reduced 8.3%	3,370,815 $8.36 Million
Q3 2021 Nov 12, 2021	BUY	$2.25 - $3.18 $22,050 - $31,164	9,800 Added 0.27%	3,676,004 $10.8 Million
Q2 2021 Aug 13, 2021	BUY	$2.16 - $2.62 $7.92 Million - $9.61 Million	3,666,204 New	3,666,204 $9.17 Million

Ticker CTIC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 114,385,000
Market Cap $1.04B
Description
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients w...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.